Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease

Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease

(2022) Joana Vieira Barbosa et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The GIPR is Predominantly Localized to Non-Adipocyte Cell Types Within White Adipose Tissue

(2022) Jonathan E. Campbell et al.   DIABETES

Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes

(2022) Richeek Pradhan et al.   DIABETES CARE

Plasma FGF21 concentrations are regulated by glucose independently of insulin and GLP-1 in lean, healthy humans

(2022) Thomas P.J. Solomon et al.   PeerJ

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

(2022) Naim Alkhouri et al.   JOURNAL OF HEPATOLOGY

A single-cell atlas of human and mouse white adipose tissue

(2022) Margo P. Emont et al.   NATURE

Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis

(2022) John J. Nestor et al.   Scientific Reports

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

(2022) Amalia Gastaldelli et al.   Lancet Diabetes & Endocrinology

Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study

(2022) Teruki Miyake et al.   Diabetes Therapy

Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression

(2021) Bruno Vergès et al.   DIABETES CARE

Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes

(2021) Kirsten Dahl et al.   DIABETES OBESITY & METABOLISM

Therapeutic pipeline in nonalcoholic steatohepatitis

(2021) Raj Vuppalanchi et al.   Nature Reviews Gastroenterology & Hepatology

Hepatic fibroblast growth factor 21 is involved in mediating functions of liraglutide in mice with dietary challenge

(2021) Dinghui Liu et al.   HEPATOLOGY

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

(2021) Lone B Enebo et al.   LANCET

Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non‐alcoholic steatohepatitis

(2021) Nikolaos Perakakis et al.   LIVER INTERNATIONAL

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

(2021) Rajaa Nahra et al.   DIABETES CARE

Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist

(2021) Rayane Miranda Pontes-da-Silva et al.   INTERNATIONAL JOURNAL OF OBESITY

The Human and Mouse Islet Peptidome: Effects of Obesity and Type 2 Diabetes, and Assessment of Intraislet Production of Glucagon-like Peptide-1

(2021) Sam G. Galvin et al.   JOURNAL OF PROTEOME RESEARCH

Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus

(2021) Daniel Ferguson et al.   Nature Reviews Endocrinology

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

(2021) Juan P. Frías et al.   NEW ENGLAND JOURNAL OF MEDICINE

Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study

(2021) Mario Luca Morieri et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Effect of liraglutide on expression of inflammatory genes in type 2 diabetes

(2021) Emilie H. Zobel et al.   Scientific Reports

Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist

(2021) Martin Bossart et al.   Cell Metabolism

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

(2021) David C W Lau et al.   LANCET

Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2021) Xinyue Li et al.   Journal of Diabetes Research

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

(2021) Naveed Sattar et al.   Lancet Diabetes & Endocrinology

Reagents and models for detecting endogenous GLP1R and GIPR

(2021) Julia Ast et al.   EBioMedicine

Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide

(2021) Brent A. McLean et al.   JCI Insight

GLP-1 physiology informs the pharmacotherapy of obesity

(2021) Daniel J. Drucker   Molecular Metabolism

MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease

(2020) Mohammed Eslam et al.   GASTROENTEROLOGY

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

(2020) Mark L. Hartman et al.   DIABETES CARE

NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications

(2020) Giovanni Targher et al.   GUT

SELECT (Semaglutide effects on cardiovascular outcomes in people with overweight or obesity) rationale and design

(2020) Donna H. Ryan et al.   AMERICAN HEART JOURNAL

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists

(2020) Shweta Urva et al.   DIABETES OBESITY & METABOLISM

Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis

(2020) Guillaume Lassailly et al.   GASTROENTEROLOGY

The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet

(2020) Emmanuel Somm et al.   Translational Research

The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

(2020) Jonathan M. Wilson et al.   DIABETES OBESITY & METABOLISM

Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)

(2020) Mohammad S. Kuchay et al.   DIABETOLOGIA

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

(2020) Laurie L. Baggio et al.   Molecular Metabolism

Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation

(2020) Brent A McLean et al.   ENDOCRINE REVIEWS

Using a reporter mouse to map known and novel sites of GLP-1 receptor expression in peripheral tissues of male mice

(2020) Daniel B Andersen et al.   ENDOCRINOLOGY

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

(2020) Philip N. Newsome et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output

(2019) Junling Liu et al.   EBioMedicine

Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease

(2019) Shun He et al.   NATURE

Incorporating Weight Loss Medications into Hepatology Practice for Nonalcoholic Steatohepatitis

(2019) Albert Do et al.   HEPATOLOGY

Distinct Neural Sites of GLP-1R Expression Mediate Physiological versus Pharmacological Control of Incretin Action

(2019) Elodie M. Varin et al.   Cell Reports

Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease

(2019) Dimitrios A. Koutoukidis et al.   JAMA Internal Medicine

Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice

(2019) Youngmi Song et al.   Cell Metabolism

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

(2019) Helena W. Rodbard et al.   DIABETES CARE

Glucagon-like peptide 1 (GLP-1)

(2019) T.D. Müller et al.   Molecular Metabolism

Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus

(2018) Bruno Vergès et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis

(2018) David H Ipsen et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

(2018) Daniel J. Drucker   Cell Metabolism

Mechanisms of NAFLD development and therapeutic strategies

(2018) Scott L. Friedman et al.   NATURE MEDICINE

Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis

(2018) Kirstine S Tølbøl et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study

(2018) Niina Matikainen et al.   DIABETES OBESITY & METABOLISM

Mouse models of nonalcoholic steatohepatitis Towards optimization of their relevance to human NASH

(2018) Geoff Farrell et al.   HEPATOLOGY

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy

(2018) M. Pilar Valdecantos et al.   Scientific Reports

Insulin Secretion Depends on Intra-islet Glucagon Signaling

(2018) Berit Svendsen et al.   Cell Reports

Discovery, characterization, and clinical development of the glucagon-like peptides

(2017) Daniel J. Drucker et al.   JOURNAL OF CLINICAL INVESTIGATION

Duodenal GLP-1 signaling regulates hepatic glucose production through a PKC-δ-dependent neurocircuitry

(2017) Mengliu Yang et al.   Cell Death & Disease

The microbiota maintain homeostasis of liver-resident γδT-17 cells in a lipid antigen/CD1d-dependent manner

(2017) Fenglei Li et al.   Nature Communications

Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion

(2017) Lorène J. Lebrun et al.   Cell Reports

Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice

(2017) Hani Jouihan et al.   Molecular Metabolism

Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease

(2017) Christian Baumeier et al.   Molecular Metabolism

Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies

(2017) Fernanda Cristina de Mesquita et al.   Scientific Reports

iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy

(2016) Lydia Lynch et al.   Cell Metabolism

The Cardiovascular Biology of Glucagon-like Peptide-1

(2016) Daniel J. Drucker   Cell Metabolism

The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice

(2016) Melissa A. Burmeister et al.   DIABETES

Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus

(2016) Y. Hu et al.   DIABETES & METABOLISM

The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

(2016) Matthew J. Armstrong et al.   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Insulin resistance, postprandial GLP-1 and adaptive immunity are the main predictors of NAFLD in a homogeneous population at high cardiovascular risk

(2016) L. Bozzetto et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain-Gut Axis

(2015) S. Farr et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R

(2015) Bernardo Yusta et al.   DIABETES

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

(2015) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

(2015) Paul Angulo et al.   GASTROENTEROLOGY

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

Oxyntomodulin regulates resetting of the liver circadian clock by food

(2015) Dominic Landgraf et al.   eLife

GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans

(2014) Sharmila C. Subaran et al.   CLINICAL SCIENCE

GLP-1 Secretion Is Increased by Inflammatory Stimuli in an IL-6-Dependent Manner, Leading to Hyperinsulinemia and Blood Glucose Lowering

(2014) F. Kahles et al.   DIABETES

GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK

(2014) D. Beiroa et al.   DIABETES

Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors

(2014) Erin E. Mulvihill et al.   ENDOCRINE REVIEWS

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

(2014) Charles Pyke et al.   ENDOCRINOLOGY

Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect

(2014) Stephanie Sisley et al.   JOURNAL OF CLINICAL INVESTIGATION

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

(2014) Brian Finan et al.   NATURE MEDICINE

Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease

(2014) Christine Bernsmeier et al.   PLoS One

GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance

(2014) Jennifer Taher et al.   Molecular Metabolism

Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration

(2013) Y Wang et al.   BRITISH JOURNAL OF PHARMACOLOGY

Lipopolysaccharides-Mediated Increase in Glucose-Stimulated Insulin Secretion: Involvement of the GLP-1 Pathway

(2013) A. T. Nguyen et al.   DIABETES

Identification and Characterization of GLP-1 Receptor-Expressing Cells Using a New Transgenic Mouse Model

(2013) P. Richards et al.   DIABETES

Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial

(2013) K. Hermansen et al.   DIABETES OBESITY & METABOLISM

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

(2013) J van Can et al.   INTERNATIONAL JOURNAL OF OBESITY

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

(2012) James L. Trevaskis et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans

(2012) Changting Xiao et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide-Dependent Mechanism

(2012) W. Chai et al.   DIABETES

Direct Control of Brown Adipose Tissue Thermogenesis by Central Nervous System Glucagon-Like Peptide-1 Receptor Signaling

(2012) S. H. Lockie et al.   DIABETES

Direct effect of GLP-1 infusion on endogenous glucose production in humans

(2012) M. Seghieri et al.   DIABETOLOGIA

GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice

(2012) Naim Panjwani et al.   ENDOCRINOLOGY

GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice

(2012) Edwin T. Parlevliet et al.   PLoS One

Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice

(2011) Melissa A. Burmeister et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet

(2011) Jamie E. Mells et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Intracellular Signals Mediating the Food Intake-Suppressive Effects of Hindbrain Glucagon-like Peptide-1 Receptor Activation

(2011) Matthew R. Hayes et al.   Cell Metabolism

Exenatide Exerts a Potent Antiinflammatory Effect

(2011) Ajay Chaudhuri et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells

(2011) Helga Ellingsgaard et al.   NATURE MEDICINE

Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes

(2011) Padma Sathyanarayana et al.   Obesity

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

(2010) Eric A. Schwartz et al.   ATHEROSCLEROSIS

Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes

(2010) M. Lazo et al.   DIABETES CARE

Glucagon-Like Peptide-1 Receptor Knockout Mice Are Protected from High-Fat Diet-Induced Insulin Resistance

(2010) Julio E. Ayala et al.   ENDOCRINOLOGY

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

(2009) J. Hsieh et al.   DIABETOLOGIA

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

(2009) Kittichai Promrat et al.   HEPATOLOGY

The Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting

(2008) Christine Longuet et al.   Cell Metabolism

Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver

(2008) D. Zheng et al.   DIABETES

Arcuate Glucagon-Like Peptide 1 Receptors Regulate Glucose Homeostasis but Not Food Intake

(2008) D. A. Sandoval et al.   DIABETES

The Glucagon-Like Peptide-1 Receptor Regulates Endogenous Glucose Production and Muscle Glucose Uptake Independent of Its Incretin Action

(2008) Julio E. Ayala et al.   ENDOCRINOLOGY